CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 121 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $304 | +1.0% | 236 | +34.9% | 0.00% | – |
| Q2 2023 | $301 | +1057.7% | 175 | +929.4% | 0.00% | – |
| Q1 2023 | $26 | -18.8% | 17 | -15.0% | 0.00% | – |
| Q4 2022 | $32 | -100.0% | 20 | -96.2% | 0.00% | – |
| Q3 2022 | $773,000 | -97.8% | 533 | -97.2% | 0.00% | – |
| Q2 2022 | $35,352,000 | +142.8% | 19,318 | +254.2% | 0.00% | – |
| Q1 2022 | $14,562,000 | -74.9% | 5,454 | -59.4% | 0.00% | – |
| Q4 2021 | $58,126,000 | -1.7% | 13,424 | +15.5% | 0.00% | – |
| Q3 2021 | $59,141,000 | +326.0% | 11,619 | +429.8% | 0.00% | – |
| Q2 2021 | $13,882,000 | -89.4% | 2,193 | -87.0% | 0.00% | – |
| Q1 2021 | $130,861,000 | +252.9% | 16,929 | +199.0% | 0.00% | – |
| Q4 2020 | $37,086,000 | -46.5% | 5,662 | -45.7% | 0.00% | – |
| Q3 2020 | $69,280,000 | +91.4% | 10,418 | +139.7% | 0.00% | – |
| Q2 2020 | $36,202,000 | -66.3% | 4,346 | -69.0% | 0.00% | – |
| Q1 2020 | $107,365,000 | +142.5% | 13,998 | +162.8% | 0.00% | – |
| Q4 2019 | $44,267,000 | -15.4% | 5,327 | -24.9% | 0.00% | – |
| Q3 2019 | $52,354,000 | -6.1% | 7,094 | +42.8% | 0.00% | – |
| Q2 2019 | $55,741,000 | -44.0% | 4,968 | -46.3% | 0.00% | – |
| Q1 2019 | $99,534,000 | +59860.2% | 9,259 | +84072.7% | 0.00% | – |
| Q4 2018 | $166,000 | -99.3% | 11 | -99.1% | 0.00% | – |
| Q3 2018 | $22,607,000 | -19.1% | 1,222 | 0.0% | 0.00% | – |
| Q2 2018 | $27,935,000 | -84.0% | 1,222 | -80.0% | 0.00% | – |
| Q1 2018 | $174,142,000 | +35.9% | 6,121 | +0.8% | 0.00% | – |
| Q4 2017 | $128,159,000 | +127.4% | 6,071 | +95.7% | 0.00% | – |
| Q3 2017 | $56,363,000 | +10.9% | 3,102 | -5.4% | 0.00% | – |
| Q2 2017 | $50,825,000 | +1126.2% | 3,279 | +1266.2% | 0.00% | – |
| Q1 2017 | $4,145,000 | -69.0% | 240 | -80.3% | 0.00% | – |
| Q4 2016 | $13,386,000 | -39.9% | 1,218 | -14.2% | 0.00% | – |
| Q3 2016 | $22,266,000 | +158.7% | 1,420 | +68.4% | 0.00% | – |
| Q2 2016 | $8,607,000 | -70.0% | 843 | -38.7% | 0.00% | – |
| Q4 2015 | $28,718,000 | – | 1,376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |